BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Not yet recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Deucravacitinib
Other: Placebo

First Posted Date: 2025-05-20

Last Posted Date: 2025-05-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 366

Registration Number: NCT06979453

Locations: 🇺🇸
Local Institution - 0025, Fountain Valley, California, United States
🇺🇸
Local Institution - 0070, Tampa, Florida, United States
🇺🇸
Local Institution - 0202, Metairie, Louisiana, United States

and more 55 locations

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Phase 3

Not yet recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: KarXT
Other: Placebo
Drug: KarX-EC

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 586

Registration Number: NCT06976216

Locations: 🇭🇷
Local Institution - 0216, Osijek, Croatia
🇭🇷
Local Institution - 0267, Rijeka, Croatia
🇭🇷
Local Institution - 0240, Zagreb, Croatia

and more 110 locations

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Phase 3

Not yet recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: KarXT
Other: Placebo
Drug: KarX-EC

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 586

Registration Number: NCT06976203

Locations: 🇫🇮
Local Institution - 0022, Oulu, Pohjois-Pohjanmaa, Finland
🇫🇮
Local Institution - 0009, Turku, Varsinais-Suomi, Finland
🇫🇮
Local Institution - 0008, Kuopio, Finland

and more 112 locations

A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

Active, not recruiting

Conditions: Myelodysplastic Syndromes (MDS)

Interventions: Drug: Luspatercept
Drug: Erythropoiesis-stimulating agent (ESA)

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 430

Registration Number: NCT06971185

Locations: 🇺🇸
Bristol Myers Squibb, Princeton, New Jersey, United States

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteer

Interventions: Drug: BMS-986446 IV
Drug: BMS-986446 SC
Drug: Acetaminophen
Drug: Loratadine

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT06955741

Locations: 🇺🇸
Local Institution - 10000, Anaheim, California, United States
🇺🇸
Anaheim Clinical Trials LLC (ACT), Anaheim, California, United States
🇺🇸
Local Institution - 9999, Anaheim, California, United States

A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: Deucravacitinib
Biological: Any biologic treatment for psoriasis

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2000

Registration Number: NCT06952465

Locations: 🇯🇵
Local Institution, Tokyo, Japan
🇯🇵
Medical Data Vision, Inc, Tokyo, Japan

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Phase 3

Not yet recruiting

Conditions: Bipolar-I Disorder With Mania or Mania With Mixed Features

Interventions: Drug: KarXT
Other: Placebo

First Posted Date: 2025-04-30

Last Posted Date: 2025-04-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 274

Registration Number: NCT06951698

Locations: 🇺🇸
Local Institution - 0058, Bentonville, Arkansas, United States
🇺🇸
Local Institution - 0011, Little Rock, Arkansas, United States
🇺🇸
Local Institution - 0005, Anaheim, California, United States

and more 58 locations

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

Phase 3

Not yet recruiting

Conditions: Bipolar Disorder Type I With Mania or Mania With Mixed Features

Interventions: Drug: KarXT
Other: Placebo

First Posted Date: 2025-04-30

Last Posted Date: 2025-05-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 274

Registration Number: NCT06951711

Locations: 🇮🇹
Local Institution - 0056, Pisa, Toscana, Italy
🇮🇹
Local Institution - 0007, Siena, Toscana, Italy
🇮🇹
Local Institution - 0041, Ancona, Italy

and more 61 locations

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Phase 3

Not yet recruiting

Conditions: Alzheimer Disease
Psychosis

Interventions: Drug: KarXT + KarX-EC Arm Matching Placebo
Drug: KarXT
Drug: KarX-EC

First Posted Date: 2025-04-27

Last Posted Date: 2025-04-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1046

Registration Number: NCT06947941

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2025-04-27

Last Posted Date: 2025-05-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT06946797

Locations: 🇵🇱
Local Institution - 0079, Łódź, Łódzkie, Poland
🇧🇷
Local Institution - 0041, Brasilia, Distrito Federal, Brazil
🇺🇸
Local Institution - 0032, Anchorage, Alaska, United States

and more 45 locations

Home Terms & Conditions Privacy Policy